Insulin Drugs Market, By Product Type (Human Insulin, Basal Insulin, Bolus Insulin, Insulin Combinations, and Biosimilar Insulin), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI380120 | Publish Date: March 2024 | No. of Pages: 178

Global Insulin Drugs Market By Overview

Introduction:

Insulin Drugs Market was valued at US$ 28.8 Billion in 2024 and is projected to grow at a CAGR of 4.2% to reach US$ 41.9 Billion by 2034.

Insulin is the protein hormone which is used to treat high blood glucose. It is also used as a medication to treat diabetes, gestational diabetes, Mellitus type 1, diabetes mellitus type 2 and complications of diabetes such as hyperosmolar hyperglycemic states and diabetic ketoacidosis. Generally, some forms of the insulin are given by injection under the skin, and some forms of insulin can also be given by injecting into muscles or veins.

Drivers and Restraints:

The government policies are favourable for the production of insulin which is the major propelling factor for the growth of the global insulin market. Additionally, the biotechnology and biopharmaceutical companies are focusing on the developing the advance medical device to deliver the insulin with less pain and safety in the body which is the boosting factor for the growth of the target market. Moreover, insulin is used to control the glycemic condition by which the risk of cardiovascular can be controlled which is another propelling factor for the growth of the global market. For instance, according to data collected by the WHO (World’s Health Organization) between the years 2016-2019 from the 24 countries, showed that the availability of human insulin is 61% of the health facilities and availability of analogue insulin is 13%. However, the cost of insulin is not affordable by everyone which is the restraining factor for the growth of the global market. Moreover, the lack of awareness about the insulin drug is another hampering factor for the growth of the target market. Nevertheless, the investment in research and development to reduce the prices of insulin can create an opportunity for the global insulin drugs market.

Segmentation:

The insulin drugs market is segmented based on product type and region.

Based on product type, the insulin drugs market is segmented into human insulin, basal insulin, bolus insulin, insulin combinations, and biosimilar insulin. Basal insulin is considered as the largest selling insulin due to less price globally and is expected to maintain its dominance during the forecast period.

Based on the region the insulin drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America region is the largest insulin selling region due to increasing diabetic patients in the region. In North America, the U.S. is the largest selling region of long-acting insulin, Lantus, across the world. Asia- Pacific region is expected to dominate the global market over the forecast period. 

Key Players:

The key players operating the insulin drugs market involves Novo Nordisk AS, Sanofi Aventis, Eli Lilly And Company, Biocon Limited, Julphar, Sedico, Pfizer, Inc., Albireo Pharma, Inc., YPSOMED Holding AG and Wockhardt Limited. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. For instance, in 2017, Novo Nordisk AS got approval for FIASP in the U.S.

Detailed Segmentation:

Insulin Drugs Market, By Product Type:

  • Human Insulin
  • Basal Insulin
  • Bolus Insulin
  • Insulin Combinations
  • Biosimilar Insulin

Insulin Drugs Market, By Region:

  • North America
    • Middle East & Africa
      • Middle East & Africa Insulin Drugs Market, By Product Type
      • Middle East & Africa Insulin Drugs Market, By Country
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
      • Latin America Insulin Drugs Market, By Product Type
      • Latin America Insulin Drugs Market, By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
      • Asia Pacific Insulin Drugs Market, By Product Type
      • Asia Pacific Insulin Drugs Market, By Country
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific                                                                                                                                                                                         
    • Europe
      • Europe Insulin Drugs Market, By Product Type
      • Europe Insulin Drugs Market, By Country
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • North America Insulin Drugs Market, By Product Type
    • North America Insulin Drugs Market, By Country
      • The U.S.
      • Canada

Company Profile:

  • Novo Nordisk AS *
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Sanofi Aventis
  • Eli Lilly and Company
  • Biocon Limited
  • Julphar
  • Albireo Pharma, Inc.
  • Sedico
  • Wockhardt Limited
  • Pfizer, Inc.
  • YPSOMED Holding AG

“*” marked represents similar segmentation in other categories in the respective section

Key Issues Addressed

  • What is the total revenue potential of the global insulin drugs market? How that market is expected to grow during the study period?
  • What are some of the major growth opportunities in the insulin drugs market?
  • Which companies are the major players in the insulin drugs market?

Global Insulin Drugs Market By Table of Contents

Global Insulin Drugs Market

Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Industry Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Insulin Drugs  Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Product Type
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Insulin Drugs  Market, By Product Type, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Human Insulin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Basal Insulin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Bolus Insulin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Insulin Combinations
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Biosimilar Insulin
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Insulin Drugs  Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  8. Company Profiles
      • Novo Nordisk AS *
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      •  Sanofi Aventis
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Eli Lilly And Company
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Biocon Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Julphar
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • ALBIREO PHARMA, INC.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • SEDICO
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • Wockhardt Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • PFIZER
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
      • YPSOMED HOLDING AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
  9. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The insulin drugs market is segmented based on product type and region.

the development of advanced insulin formulations, the focus on personalized insulin therapies, and advancements in insulin delivery devices, presenting significant opportunities in the global Insulin Drugs Market.

increasing prevalence of diabetes, advancements in insulin analogs and biosimilars, the growing demand for convenient insulin delivery systems, and the rise of personalized medicine in diabetes management.

North America and Europe are expected to dominate the Insulin Drugs Market, driven by a high prevalence of diabetes, well-established healthcare systems, and significant market presence of key players in these regions.

The key players operating the global insulin drugs market involves Novo Nordisk AS, Sanofi Aventis, Eli Lilly And Company, Biocon Limited, Julphar, Sedico, Pfizer, Inc., Albireo Pharma, Inc., YPSOMED Holding AG and Wockhardt Limited.